Pharming Group (NASDAQ:PHAR) Reaches New 52-Week Low – Should You Sell?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) shares hit a new 52-week low on Tuesday. The company traded as low as $9.38 and last traded at $9.51, with a volume of 8,724 shares trading hands. The stock had previously closed at $9.61.

Wall Street Analyst Weigh In

PHAR has been the topic of several research reports. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, September 22nd. Canaccord Genuity Group set a $38.00 target price on Pharming Group in a report on Wednesday, September 23rd. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $38.67.

Pharming Group Stock Performance

The firm’s 50-day moving average is $10.95 and its 200 day moving average is $13.01. The stock has a market cap of $673.10 million, a PE ratio of 79.25 and a beta of -0.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. As a group, research analysts anticipate that Pharming Group N.V. Sponsored ADR will post 0.22 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises approximately 6.0% of MAC Alpha Capital Management LP’s holdings, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with significant unmet medical needs, using biotechnology and protein-replacement approaches.

Pharming’s commercial products include Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral therapy for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency disorder.